NCT05498220 2026-04-16
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
Clinical Trials
5 trialsNCT01241734 2026-04-08
RICER
Hackensack Meridian Health
Phase 1/2 Completed
NCT03570892 2026-04-08
BELINDA
Novartis
Phase 3 Completed
NCT01679119 2026-04-07
INCA
University College, London
Phase 2 Completed
NCT05068440 2026-03-25
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
BeOne Medicines
Phase 2 Completed